OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
NIVA58

Niva Bupa Health Insurance Company Ltd

Life & Health InsuranceVerified

Niva Bupa maintains a conservative capital structure with a debt-to-equity ratio of 0.07, indicating minimal leverage and strong equity backing. The company's liquidity position is assessed as medium, with free cash flow of INR 1.97 billion and operating cash flow of INR 16.54 billion, but net cash is negative after subtracting total debt. This suggests that while the company generates robust cash from operations, it is currently using cash to service or reduce debt obligations. Profitability metrics show a return on equity (ROE) of 5.65% and a return on assets (ROA) of 2.04%. These figures are below the industry median for ROE and ROA in the Life & Health Insurance sector, indicating that Niva Bupa is underperforming relative to its peers in terms of capital efficiency and asset utilization. The company's revenue is concentrated in its core health and life insurance segments, with no material geographic diversification beyond India. This concentration exposes the company to regulatory and macroeconomic risks specific to the Indian market, particularly in the insurance sector, which is subject to evolving policy frameworks and consumer behavior shifts. Looking ahead, Niva Bupa is projected to experience moderate growth in the current fiscal year, with revenue and operating income expected to increase by low single-digit percentages. The company's capital expenditure has been negative in recent periods, suggesting a focus on cost optimization rather than expansion. Analysts have assigned a mean recommendation of 1.89, indicating a generally positive outlook, with 3 strong-buy and 4 buy ratings. Risk factors include the company's reliance on a single market and the potential for regulatory changes affecting premium pricing and claims management. The risk of dilution is assessed as low, with no significant share issuance activity in the recent financial period. However, the negative net cash position after debt suggests that the company may need to access external financing in the near term, which could introduce new risks. Recent filings and transcripts indicate that Niva Bupa is focused on expanding its digital offerings and improving customer retention in a competitive market. The company has also emphasized its investment strategy, which is aligned with maintaining a strong balance sheet and generating stable returns for shareholders.

30-day price · NIVA+9.77 (+13.1%)
Low$71.86High$89.77Close$84.08As of26 May, 00:00 UTC
Profile
CompanyNiva Bupa Health Insurance Company Ltd
TickerNIVA.NS
SectorFinancials
BusinessInsurance
Industry groupInsurance
IndustryLife & Health Insurance
AI analysis

Business. Niva Bupa Health Insurance Company Ltd provides health and life insurance products in India, generating revenue primarily through premium income and investment returns on its insurance reserves.

Classification. Niva Bupa is classified under the Life & Health Insurance industry within the Financials sector, with a high confidence level of 0.92 based on verified market data.

Niva Bupa maintains a conservative capital structure with a debt-to-equity ratio of 0.07, indicating minimal leverage and strong equity backing. The company's liquidity position is assessed as medium, with free cash flow of INR 1.97 billion and operating cash flow of INR 16.54 billion, but net cash is negative after subtracting total debt. This suggests that while the company generates robust cash from operations, it is currently using cash to service or reduce debt obligations. Profitability metrics show a return on equity (ROE) of 5.65% and a return on assets (ROA) of 2.04%. These figures are below the industry median for ROE and ROA in the Life & Health Insurance sector, indicating that Niva Bupa is underperforming relative to its peers in terms of capital efficiency and asset utilization. The company's revenue is concentrated in its core health and life insurance segments, with no material geographic diversification beyond India. This concentration exposes the company to regulatory and macroeconomic risks specific to the Indian market, particularly in the insurance sector, which is subject to evolving policy frameworks and consumer behavior shifts. Looking ahead, Niva Bupa is projected to experience moderate growth in the current fiscal year, with revenue and operating income expected to increase by low single-digit percentages. The company's capital expenditure has been negative in recent periods, suggesting a focus on cost optimization rather than expansion. Analysts have assigned a mean recommendation of 1.89, indicating a generally positive outlook, with 3 strong-buy and 4 buy ratings. Risk factors include the company's reliance on a single market and the potential for regulatory changes affecting premium pricing and claims management. The risk of dilution is assessed as low, with no significant share issuance activity in the recent financial period. However, the negative net cash position after debt suggests that the company may need to access external financing in the near term, which could introduce new risks. Recent filings and transcripts indicate that Niva Bupa is focused on expanding its digital offerings and improving customer retention in a competitive market. The company has also emphasized its investment strategy, which is aligned with maintaining a strong balance sheet and generating stable returns for shareholders.
Key takeaways
  • Niva Bupa has a conservative capital structure with a low debt-to-equity ratio of 0.07.
  • The company's ROE of 5.65% and ROA of 2.04% are below the industry median, indicating underperformance in capital efficiency.
  • Revenue is concentrated in India, exposing the company to regulatory and macroeconomic risks.
  • Analysts project moderate growth with a mean recommendation of 1.89, suggesting a generally positive outlook.
  • The company's liquidity position is medium, with a negative net cash position after subtracting total debt.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyINR
Revenue
Gross profit
Operating income$1.79B
Net income$2.14B
R&D
SG&A
D&A
SBC
Operating cash flow$16.54B
CapEx-$414.2M
Free cash flow$1.97B
Total assets$104.79B
Total liabilities$67.02B
Total equity$37.76B
Cash & equivalents
Long-term debt$2.50B
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$37.76B
Net cash-$2.50B
Current ratio
Debt/Equity0.1
ROA2.0%
ROE5.7%
Cash conversion7.8%
CapEx/Revenue
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Life & Health Insurance · cohort 15 companies
MetricNIVAActivity
Op margin12.3% medp25 5.6% · p75 21.6%
Net margin2.9% medp25 0.5% · p75 10.1%
Gross margin28.2% medp25 13.4% · p75 30.5%
CapEx / revenue-2.1% medp25 -8.2% · p75 -1.2%
Debt / equity7.0%27.5% medp25 4.7% · p75 66.5%below median
Observations
IR observations
Mean price target86.67 INR
Median price target85.00 INR
High price target95.00 INR
Low price target78.00 INR
Mean recommendation1.89 (1=strong buy, 5=strong sell)
Strong-buy count3.00
Buy count4.00
Hold count2.00
Sell count0.00
Strong-sell count0.00
Mean EPS estimate0.72 INR
Last actual EPS1.20 INR
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod financials
no public URL
2026-05-22 18:10 UTC#51a21d16
Source: analysis-pipeline (hybrid)Generated: 2026-05-28 18:16 UTCJob: 2b93bfbb